Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1998 1
2004 1
2010 1
2015 1
2016 3
2017 1
2019 2
2020 6
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Dimopoulos MA, et al. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. Lancet Oncol. 2021. PMID: 34087126 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Pesg PNH diagnosis, follow-up and treatment guidelines.
Sahin F, Akay OM, Ayer M, Dal MS, Ertop S, Ilhan O, Karakus V, Ozcan MA, Ozkocaman V, Ozsan H, Salim O, Tobu M, Tombak A, Tuglular TF, Yilmaz M, Unal A, Yenerel MN, Saydam G. Sahin F, et al. Among authors: tuglular tf. Am J Blood Res. 2016 Aug 5;6(2):19-27. eCollection 2016. Am J Blood Res. 2016. PMID: 27570707 Free PMC article. Review.
Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura.
Arıkan F, Yıldız Y, Ercan T, Oruç Ö, Akçay S, Yılmaz F, Toptaş T, Tuğlular T. Arıkan F, et al. Among authors: tuglular t. Turk J Haematol. 2020 Nov 19;37(4):302-304. doi: 10.4274/tjh.galenos.2020.2020.0322. Epub 2020 Jul 23. Turk J Haematol. 2020. PMID: 32702948 Free PMC article. No abstract available.
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS, Ulu BU, Uzay A, Akay OM, Beşışık S, Yenerel MN, Çelik S, Kaynar L, Yücel OK, Deveci B, Sönmez M, Mehtap Ö, Beköz HS, Sunu C, Salim O, Ulaş T, Kartı S, Altuntaş F, Ferhanoğlu B, Tuğlular TF. Dal MS, et al. Among authors: tuglular tf. Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401621 Free PMC article.
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, Tuglular T, Vural F, Yagci M, Alacacioglu I, Aytan P, Goksoy HS, Gulbas Z, Gunes AK, Gurkan E, Hacioglu SK, Karti SS, Kaynar L, Ozdogu H, Paydas S, Solmaz S, Sonmez M, Tekgunduz E, Yildirim R, Ilhan O. Beksac M, et al. Among authors: tuglular t. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e474-e484. doi: 10.1016/j.clml.2020.02.017. Epub 2020 Mar 7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482539 Free article. Review.
24 results